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Abstract
Background: Diabetes mellitus is a devastating metabolic disease. Generation of insulin-producing cells (IPCs) from
stem cells, especially from Wharton’s jelly mesenchymal stem cells (WJ-MSCs), has sparked much interest recently.
Exendin-4 has several beneficial effects on MSCs and β cells. However, its effects on generation of IPCs from WJ-MSCs
specifically have not been studied adequately. The purpose of this study was therefore to investigate how exendin-4
could affect the differentiation outcome of WJ-MSCs into IPCs, and to investigate the role played by exendin-4 in this
differentiation process.
Methods: WJ-MSCs were isolated, characterized and then induced to differentiate into IPCs using two differentiation
protocols: protocol A, without exendin-4; and protocol B, with exendin-4. Differentiated IPCs were assessed by
the expression of various β-cell-related markers using quantitative RT-PCR, and functionally by measuring glucose-
stimulated insulin secretion.
Results: The differentiation protocol B incorporating exendin-4 significantly boosted the expression levels of
β-cell-related genes Pdx-1, Nkx2.2, Isl-1 and MafA. Moreover, IPCs generated by protocol B showed much better
response to variable glucose concentrations as compared with those derived from protocol A, which totally
lacked such response. Furthermore, exendin-4 alone induced early differentiation markers such as Pdx-1 and
Nkx2.2 but not Isl-1, besides inducing late markers such as MafA. In addition, exendin-4 showed a synergistic
effect with nicotinamide and β-mercaptoethanol in the induction of these markers.
Conclusions: Exendin-4 profoundly improves the differentiation outcome of WJ-MSCs into IPCs, possibly through the
ability to induce the expression of β-cell markers.
Keywords: Wharton’s jelly, Mesenchymal stem cells, Exendin-4, Insulin-producing cells, Diabetes mellitus
Background
Diabetes mellitus (DM) is a devastating metabolic dis-
ease associated with increased morbidity and mortality
[1]. It is growing at an alarming rate, affecting more than
415 million people worldwide [2]. In DM, insulin-
secreting β cells are damaged to different extents, lead-
ing to either absolute or relative insulin deficiency in
type 1 and type 2 DM, respectively [1].
The transplantation of pancreatic islets has been dem-
onstrated as a very effective treatment for DM, which
could allow temporal insulin independence [3]. How-
ever, the availability of the donor islets could never meet
the demand of the DM burden, which firmly establishes
the clinical value of generating surrogate β cells from al-
ternative renewable sources such as differentiation from
stem cells [4].
Actually, within the last few years, various types of
stem cells have been shown to be able to give rise to
insulin-producing cells (IPCs), including embryonic stem
cells (ESCs) [5, 6] and mesenchymal stem cells (MSCs)
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[7–9]. In fact, MSCs could indeed represent the stem
cells of choice for regenerative medicine [10]. Among
the various sources of MSCs, the umbilical cord (UC)
together with other extra-embryonic tissues, which are
routinely discarded at parturition, provide an untapped
source of MSCs [11]. These sources do not impose any
ethical concerns such as those which exist regarding
ESCs, thus implying great potential for biomedical appli-
cations and cell-based therapeutic approaches [12].
The UC has been proved to be a good source of
MSCs either from cord blood or cord tissue, also
known as Wharton’s jelly (WJ) MSCs. The main fascin-
ation of WJ-MSCs lies in their possible banking, ease of
isolation and large ex-vivo expansion capacity, as well
as their demonstrated multipotency and immunomodu-
latory activities, which nominate them to become the
new gold standard for MSC-based therapies [10]. Actu-
ally, in the context of diabetes research, WJ-MSCs
sparked great interest [13] that is further encouraged
by the recent interesting findings of multiple beneficial
effects upon their injection into either diabetic patients
or animals. Interestingly, Liu et al. applied WJ-MSC
transplantation in type 2 DM patients, and demon-
strated that treatment with WJ-MSCs can indeed im-
prove metabolic control and β-cell function in patients
with type 2 DM. They also suggested that their mech-
anism of action may have involved improvements in
systemic inflammation [14]. Furthermore, another re-
port highlighted the effect of intravenous infusion of
human WJ-MSCs as a therapy by administering these
cells in a type 2 DM rat model. The rats treated with
WJ-MSCs exhibited increased numbers of β cells, suggest-
ing the therapeutic potential of WJ-MSCs in β-cell regener-
ation [15]. Interestingly, our laboratory reported previously
that WJ-MSCs exhibited better differentiation potential
and control of hyperglycemia in streptozotocin-induced
diabetic rats as compared with cord blood MSCs [16].
It is noteworthy here that there are several protocols
used for generation of IPCs from MSCs in the litera-
ture. These protocols employ a huge variety of extrinsic
factors [17, 18] and induction periods, which could vary
from several days [9] to several months [17, 19]. Never-
theless, despite all of the vigorous efforts to generate
mature functioning β cells from MSCs or even other
types of stem cells, the majority of the obtained IPCs
mostly fail to properly secrete insulin in response to
glucose, and the reason for such anomalies together
with the mechanisms through which differentiation
occurs are far from complete elucidation [20].
Interestingly, the glucagon-like peptide-1 (GLP-1) re-
ceptor agonist exendin-4 [21] has been incorporated
among the various inducing extrinsic factors for the dif-
ferentiation of stem cells from various sources to IPCs
[22–24]. Exendin-4 is a 39-amino-acid peptide which
was initially isolated from the venom of lizard Heloderma
suspectum [25]. Exendin-4 has been found to act as a
long-acting GLP-1 receptor agonist which, like GLP-1, has
been reported to stimulate both β-cell replication and
neogenesis, resulting in increased β-cell mass and im-
proved glucose tolerance [26].
However, the effects of exendin-4 on the differenti-
ation of WJ-MSCs specifically have not been studied
adequately. Given the unique transcriptomic profile of
WJ-MSCs [27] and their increasingly important poten-
tial for regenerative medicine applications [28], opti-
mizing efficient differentiation protocols for these cells
is strongly warranted.
The purpose of this study was therefore to investigate
the role of exendin-4 in the generation of IPCs from WJ-
MSCs. In addition, we examined the effect of exendin-4
alone and in combination with other extrinsic factors on
the expression of β-cell markers to gain more insight into
the role played by exendin-4 in this differentiation process.
Methods
Isolation and culture of WJ-MSCs
All of the experiments were carried out in accordance
with the approved guidelines and all of the procedures
were approved by the ethical committees of both the
Faculty of Pharmacy and the Faculty of Medicine, Ain
Shams University, Cairo, Egypt. The UCs were obtained
from the Gynecology and Obstetrics Department, Ain
Shams University Hospitals, from both cesarean section
and normal labor after obtaining signed informed consent
from the parents. Fresh human UCs were collected in
sterile phosphate-buffered saline (PBS), maintained in ice
and processed within 1–4 hours post delivery. To avoid
any chance for contamination, the collected UC was
swabbed with 70 % alcohol for just a few seconds and then
washed twice with sterile PBS. Afterwards, it was cut into
smaller pieces (each 2–5 cm long). All isolation proce-
dures were carried out under aseptic conditions. The cord
blood vessels were removed and the UC WJ was processed
until obtaining single cells by the explant method as de-
scribed previously with few modifications [11, 29]. The
WJ was cut into small pieces (5–10 mm) which were
placed in six-well plates with complete low-glucose
Dulbecco’s modified Eagle’s medium (LG-DMEM) sup-
plied with 10 % FBS, 2 mM L-glutamine, 100 U/ml
penicillin and 100 μg/ml streptomycin, and subse-
quently incubated in 37 °C, 5 % CO2 humidified atmos-
phere. Adherent fibroblast-like cells appeared after 10–14
days. These cells were subcultured using 0.05 % trypsin–
EDTA, and medium was changed every other day.
Immunophenotyping of WJ-MSCs
WJ-MSCs at the third passage were trypsinized and
washed twice with PBS, and then 100,000 cells were
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incubated at 4 °C in the dark for 20 minutes with human
monoclonal antibodies labeled with either fluroisothio-
cyanate (FITC) or phycoerythrin (PE) as follows: CD34
PE, CD14 PE (BD, Pharmingen), CD73 FITC, CD90
FITC, CD105 PE (Beckman Coulter, Marseille, France).
Mouse isotype IgG1 FITC and PE antibodies were
employed as controls. The cells were then washed and
suspended in 500 μl of FACS buffer and analyzed by a
CYTOMICS FC 500 Flow Cytometer (Beckman Coulter,
FL, USA) using CXP Software version 2.2.
Differentiation of WJ isolated cells into adipogenic,
osteogenic and chondrogenic lineages
We performed adipogenic, osteogenic and chondrogenic
differentiation using the Human Mesenchymal Stem Cell
Functional Identification Kit (R&D Systems Inc., MN,
USA). The induction processes for the three lineages
were performed according to the manufacturer’s instruc-
tions. Noninduced control WJ-MSCs were fed with
complete growth medium (10 % FBS LG-DMEM) on the
same schedule of each investigated lineage. Regarding
adipogenic differentiation, after about 7 days lipid vacu-
oles started to appear in the induced cells. The detection
of the resultant differentiated cells was carried out
using Oil Red staining (Sigma-Aldrich, USA). For the
osteogenic lineage, cells changed from spindle shaped
to cuboidal shaped during differentiation, and differen-
tiation was confirmed by Alizarin Red-S staining
(Sigma-Aldrich, USA) for the calcium-rich extracellular
matrix. Finally, regarding chondrogenic induction, cells
changed from spindle shaped to cuboidal shaped during
differentiation, and differentiation was confirmed by
Alcian 8GX blue staining (Sigma-Aldrich, USA) for sul-
fated proteoglycan.
Pancreatic endocrine differentiation
After two to four passages, 1 × 106 WJ-MSCs were in-
duced to differentiate into IPCs using two protocols. The
first protocol (A) was carried out as described previously
with slight modifications [9]; cells were preinduced for
48 hours with 10 mmol/L nicotinamide (Sigma-Aldrich,
USA) and 1 mmol/L β-mercaptoethanol (Sigma-Aldrich,
USA) in 10 % FBS LG-DMEM, and then reinduced for
another 24 hours with 10 mmol/L nicotinamide and
1 mmol/L β-mercaptoethanol in serum-free high glu-
cose (HG)-DMEM.
The second protocol (B) started exactly as protocol A;
the cells were preinduced for 48 hours with 10 mmol/L
nicotinamide and 1 mmol/L β-mercaptoethanol in 10 %
FBS LG-DMEM, and then reinduced for another
24 hours with 10 mmol/L nicotinamide and 1 mmol/L
β-mercaptoethanol in serum-free HG-DMEM. However,
this was followed by further induction for 7 days by
10 nmol/L exendin-4 (Sigma-Aldrich, USA) in serum-
free HG-DMEM supplemented with 10 mmol/L nico-
tinamide and 1 mmol/L β-mercaptoethanol. Noninduced
control WJ-MSCs were fed with complete growth
medium (10 % FBS LG-DMEM) and kept for the same
time as the differentiation protocol following the same
culturing conditions as described earlier in this study.
Effect of exendin-4 alone and in combination with other
extrinsic factors on β-cell markers
Briefly, WJ-MSCs were cultured for 10 days in 5 % FBS
HG-DMEM, supplemented with either 10 nmol/L exendin-
4 alone, 10 nmol/L exendin-4 and 10 mmol/L nicotinamide,
or 10 nmol/L exendin-4 together with 10 mmol/L nicotina-
mide and 1 mmol/L β-mercaptoethanol. Noninduced con-
trol WJ-MSCs were fed with complete growth medium
(10 % FBS LG-DMEM) and kept for the same time as the
induced cells following the same culturing conditions as de-
scribed earlier in this study. RNA extraction and quantita-
tive reverse transcriptase PCR (qRT-PCR) analyses were
then performed on the resulting cells for various β-cell
markers.
RNA extraction and real-time RT-PCR analysis
Both control undifferentiated WJ-MSCs and differenti-
ated IPCs (resulting from both protocols) were col-
lected. RNA was isolated using TRIzol Reagent (Life
Technologies, USA) according to the manufacturer’s
instructions. Briefly, 3 × 106 cells were treated by 1 ml
TRIzol followed by extraction using chloroform and
isopropanol. The cDNA was prepared by the Verso™
cDNA synthesis kit (Thermo Scientific, USA) using
0.5 μg RNA. Each qRT-PCR reaction was performed
using 4 ng cDNA using the SYBR Green Master Mix
(Applied Biosystems, USA). GAPDH was used as an
internal control. ΔΔCt was used to calculate relative
expression levels. RNA expression of various pancreatic
development markers was measured by qRT-PCR. For-
ward and reverse primers for target genes are pre-
sented in Table 1. All qRT-PCR analyses were carried
out using Step-One plus qRT-PCR (Applied Biosys-
tems, USA).
Table 1 Forward and reverse primer sequences used for reverse
transcriptase PCR
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Functional assessment of differentiated cells by glucose
challenge test for insulin release (GSIS assay)
The maturity of differentiated IPCs was assessed by its
ability to secrete insulin in response to high glucose chal-
lenge. Briefly, the differentiated cells were washed twice
with PBS and Krebs Ringer bicarbonate (KRB) buffer, and
then incubated for 1 hour in KRB buffer supplemented
with 5.5 mM glucose in 37 °C, 5 % CO2 humidified atmos-
phere. Afterwards, cells were incubated with 5.5 mM glu-
cose for 1 hour and then with 16.7 mM glucose in KRB
buffer in the same conditions for 1 hour, and the super-
natant was collected at the end of each incubation and
frozen at –80 °C until the time of the assay. Insulin release
was detected by the Accubind® insulin enzyme-linked im-
munosorbent assay (Monobind Inc., CA, USA) according
to the manufacturer’s instructions.
Dithizone staining
About 1 × 105 cells/well were seeded in six-well culture
plates and exposed to various differentiation protocols.
At the end of each differentiation protocol, Dithizone
(DTZ) staining was performed to confirm IPC differenti-
ation as described previously [30]. A stock solution of
DTZ was prepared as follows: 50 mg of DTZ (Sigma
Aldrich, USA) was completely dissolved in 5 ml of di-
methyl sulfoxide (DMSO) and stored at –20 °C in the
dark. For staining, a working solution was prepared by
diluting the stock solution 1:100 in culture medium and
then filtered through a 0.2-μm nylon filter. Then 3 ml of
DTZ working solution was added to each well and incu-
bated for at least 30 minutes at 37 °C. The cells were
then carefully washed three times by PBS. Crimson red-
stained IPCs were observed under an inverted phase-
contrast microscope. Uninduced WJ-MSCs cultured in
complete growth medium (LG-DMEM supplemented
with 10 % FBS) were used as control.
Statistical analyses
Data are presented as mean ± standard error of mean.
Comparisons between the groups were conducted using
a t test. For experiments with more than two groups
comparison between means was conducted using one-
way ANOVA, and the Bonferroni post-hoc test was
applied to compare individual groups. All statistical ana-
lyses were carried out using the Windows-based SPSS
statistical package (SPSS version 17.0; SPSS, Chicago, IL,
USA). p < 0.05 was considered significant.
Results
WJ is a potential source of MSCs exhibiting all MSC
characteristics
Adherent cells with fibroblast-like morphology could be
observed as early as 10–14 days post plating of the ex-
plants of UC WJ. As shown in Fig. 1a, these cells were
almost homogeneous, resembling MSC morphology.
These cells showed excellent culture properties. Further-
more, these isolated fibroblast-like cells exhibit all of the
MSC characteristics defined by the International Society
for Cellular Therapy (ISCT) [31]. First, they were plastic
adherent. Second, we performed flow cytometry for
MSCs and hematopoietic specific cluster of differenti-
ation (CD) markers. As shown in Fig. 1b, immunophe-
notyping revealed that isolated cells were negative for
CD34 (hematopoietic stem cells) and CD14 (mono-
cytes); the percentage of cells expressing these CDs did
not exceed 5 %. On the contrary, they were positive for
MSC markers CD73, CD90 and CD105, exhibiting
expression intensities of 99.2 %, 99.9 % and 98.6 % re-
spectively for these markers. These results indicate a
relatively homogeneous mesenchymal phenotypic popula-
tion of WJ-MSCs.
As a functional assay to further confirm the MSC
identity of isolated cells, we examined the differenti-
ation potential of these cells towards mesenchymal lin-
eages. As shown in Fig. 1c–h, these WJ-MSCs exhibit
adipogenic differentiation potential; detected by Oil
Red staining of lipid droplets in comparison with con-
trol undifferentiated cells. Furthermore, these cells
show an osteogenic differentiation potential; detected
by Alizarin Red-S staining for calcium-rich extracellular
matrix as compared with their control uninduced coun-
terparts. Finally, the chondrogenic differentiation po-
tential of the isolated WJ-MSCs was detected by Alcian
8GX blue staining for sulfated proteoglycan in compari-
son with control uninduced cells.
Exendin-4 improves the differentiation outcome of
WJ-MSCs to IPCs
For generation of IPCs from WJ-MSCs, we tried two
protocols: protocol A without exendin-4; and protocol B
with exendin-4. As shown in Fig. 2a–d, at the end of
both protocols the cells tended to lose their fibroblast-
like shape and formed aggregates. Furthermore, some
cells started to detach and grew as a suspension in cul-
ture media. However, control undifferentiated cells for
both protocols kept their fibroblast-like morphology
throughout the whole protocol period. Interestingly,
when staining the resulting putative IPCs with DTZ, the
resulting differentiated cells from both protocols were
positively stained by DTZ as shown in Fig. 2e–h.
To functionally assess the IPCs generated with these
protocols, we performed glucose-stimulated insulin se-
cretion (GSIS) for the derived IPCs. As shown in Fig. 2i,
IPCs generated by protocol A did not show any response
to variable glucose concentrations (LG 5.5 mM: 5.3 ±
0.12 μIU/ml secreted insulin, HG 16.7 mM: 5.43 ± 0.01
μIU/ml secreted insulin, p = 0.339). However, IPCs gen-
erated by protocol B showed higher secretion of insulin
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in response to HG as compared with LG concentrations
(LG 5.5 mM: 7.45 ± 0.3 μIU/ml secreted insulin, HG
16.7 mM: 11.36 ± 1.23 μIU/ml secreted insulin, p =
0.037). So far, these results indicate better differentiation
of IPCs generated by protocol B. Moreover, we examined
the expression of Pdx-1 in differentiated IPCs generated
from WJ-MSCs using the two protocols by immunocyto-
chemistry. As shown in Additional file 1: Figure S1
(uppermost panel), control undifferentiated cells obvi-
ously lacked Pdx-1 expression. Upon exposure of these
cells to protocol A (middle panel) they failed to express
Pdx-1, indicating failure of this protocol to induce
proper differentiation. On the contrary, using protocol
B (lowest panel) the cells showed expression of Pdx-1,
indicating differentiation of these cells into IPCs.
In spite of similar morphological changes, the mRNA
expression levels of β-cell-related genes were quite dif-
ferent between these protocols. As shown in Fig. 3a–d,
the induced cells derived from protocol A showed rela-
tively no elevation at all for Pdx-1 expression, a slight
modest elevation of the expression levels of Nkx2.2 and
Isl-1, and elevation of MafA transcript levels. However,
for protocol B the induced cells showed a profound sig-
nificant elevation for the expression levels of Pdx-1,
Nkx2.2, Isl-1 and MafA, as compared with their control
uninduced counterparts.
Exendin-4 alone can induce Pdx-1, Nkx2.2 and MafA but
not Isl-1, while exhibiting a synergistic effect with
nicotinamide and β-mercaptoethanol
To gain more insight into the role played by exendin-4
alone and in combination with other extrinsic factors
on the differentiation markers of WJ-MSCs into IPCs,
we incubated the cells with exendin-4 alone and in
combination with nicotinamide alone or nicotinamide
plus β-mercaptoethanol. As shown in Fig. 4a, exendin-4
alone induced the Pdx-1 expression level. This eleva-
tion was further induced by adding nicotinamide and
β-mercaptoethanol to significant levels as compared
with the control group. Also, as shown in Fig. 4b,
exendin-4 showed an induction of Nkx2.2 transcript
level as compared with the control group. However, in
Fig. 1 a Phase-contrast image of isolated WJ-MSCs (passage 3) showing homogeneous fibroblast-like cells. Magnification: 10×; scale bar = 100 μm.
b Immunophenotyping for isolated WJ-MSCs; cells were labeled with FITC-conjugated or PE-conjugated antibodies and examined by flow
cytometry. The immunophenotyping profile of WJ-MSCs showed negative for CD34 and CD14 but positive for CD73, CD90 and CD105. c–h
Differentiation of isolated cells down several mesenchymal lineages: c uninduced WJ-MSCs as control for adipogenic differentiation; d induced WJ-MSCs
showing red staining of oil droplets using Oil Red, characteristic for successful adipogenic differentiation; e uninduced control WJ-MSCs for
osteogenic differentiation experiment; f induced WJ-MSCs showing positive Alizarin Red-S staining for calcium-rich extracellular matrix, indicating
successful osteogenic differentiation characteristic for MSCs; g uninduced control WJ-MSCs for the chondrogenic differentiation experiment; h induced
WJ-MSCs showing blue staining by Alcian 8GX blue for sulfated proteoglycan, indicating the successful chondrogenic differentiation of
isolated WJ-MSCs. Scale bar = 100 μm
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contrast to Pdx-1, addition of nicotinamide and β-
mercaptoethanol did not show any further elevation in
the expression levels of this transcription factor. Inter-
estingly, Fig. 4c clearly illustrated that exendin-4 alone
failed to induce the expression of Isl-1, while adding
nicotinamide and β-mercaptoethanol with exendin-4
induced increased expression levels of Isl-1. Again, as
shown in Fig. 4d, the MafA expression level showed a
slight elevation with exendin-4 alone. However,
addition of nicotinamide and β-mercaptoethanol with
exendin-4 significantly induced further elevation of
MafA levels as compared with the control group.
Discussion
In the current study, we isolated WJ-MSCs and inves-
tigated their differentiation into IPCs using two differ-
entiation protocols; with or without exendin-4. Our
results showed that WJ-MSCs indeed fulfilled all MSC
characteristics, and showed good potential to differen-
tiate into IPCs. Additionally, exendin-4 was found to
have profound beneficial effects on the differentiation
outcome of those WJ-MSCs into IPCs. Besides, al-
though our results showed that exendin-4 alone can
induce the expression of some β-cell markers, namely
Pdx-1, Nkx2.2 and MafA but not Isl-1, there still exists
a synergistic effect on the induction of such markers
upon addition of nicotinamide and β-mercaptoethanol
with overall improvement of differentiation outcome.
Strategies to create surrogate β cells for therapeutic re-
placement have ignited significant excitement over the
last decade, which has fueled profound interest in deriv-
ing functioning IPCs from stem cells [32]. Our results
regarding the observed ease of isolation and relatively
homogeneous population of isolated WJ-MSCs came in
accordance with all of the reports highlighting the im-
portant potential of WJ-MSCs for various regenerative
medicine applications [28].
Despite all efforts so far regarding the differentiation
of stem cells to IPCs, current protocols are not opti-
mized for different reasons, including the pleotropic ef-
fects induced by individual morphogens, together with
the complexity of the signaling pathways involved and
Fig. 2 a–d Phase-contrast images of differentiated IPCs obtained from WJ-MSCs after induction by differentiation protocols: upon differentiation,
cells lose their fibroblastic morphology and tend to aggregate forming clusters, which tend to detach and grow in suspension media, in contrast
to their control WJ-MSCs which retain fibroblast-like morphology. Magnification, 20×; scale bar = 20 μm. e–h Phase-contrast images of generated
IPCs stained by Dithizone (DTZ): e uninduced WJ-MSCs as a control showing negative DTZ staining; f IPCs generated by protocol A showing
positive crimson red staining by DTZ; g uninduced WJ-MSCs as a control showing negative DTZ staining; h IPCs generated by protocol B
showing positive crimson red staining by DTZ. Magnification 40×; scale bar = 20 μm. i In-vitro GSIS assay for differentiated IPCs derived from
protocol A (without exendin-4) and protocol B (with exendin-4); insulin release in response to either 5.5 mM or 16.7 mM glucose concentrations was
measured after 1 hour of incubation. It is noteworthy that control uninduced undifferentiated WJ-MSCs did not show any detectable levels of secreted
insulin in response to either 5.5 mM or 16.7 mM glucose concentrations. Results presented as mean ± standard error of mean, obtained from
three independent experiments. *Means are significantly different from secreted insulin levels in response to 5.5 mM glucose at p < 0.05. GSIS
glucose-stimulated insulin secretion, HG high glucose, LG low glucose
Kassem et al. Stem Cell Research & Therapy  (2016) 7:108 Page 6 of 11
differences between the various types of used stem cells
[18]. Further exploration into the differentiation of sev-
eral stem cells to IPCs is thus indeed warranted together
with investigating the various effects of incorporated in-
ducing factors in the differentiation process [17, 33].
In the current study, we investigated two differenti-
ation protocols, namely protocol A (without exendin-4)
and protocol B (with exendin-4). Actually, both proto-
cols induced the cells to detach and form clusters, and
both of them showed positive DIZ staining; no apparent
morphological differences were thus observed in IPCs
generated from both protocols. Interestingly, the IPCs
derived from protocol B, with exendin-4, showed a pro-
found induction for the expression levels of all investi-
gated β-cell-related genes in the current study, Pdx-1,
Nkx2.2, Isl-1 and MafA, as compared with their control
uninduced WJ-MSCs. These beneficial effects were fur-
ther extended to our observations in the GSIS assay in
which IPCs generated by protocol B demonstrated a
reasonable response to HG as compared with LG con-
centrations, while those generated from protocol A
totally lacked such response. Moreover, when carrying
out immunocytochemistry to detect Pdx-1 in IPCs gener-
ated by both protocols, those generated by protocol B
clearly expressed Pdx-1 but those derived from protocol A
did not show such clear expression. Those findings also
imply failure of protocol A lacking exendin-4 to induce
proper differentiation, and further highlight the beneficial
effects of exendin-4 on the differentiation outcome.
Moreover, exendin-4 could enhance the viability of the
generated IPCs as shown in Additional file 1: Figure S2.
Actually, this might be attributed to the beneficial effects
which have been reported recently for exendin-4 regard-
ing improving MSC proliferation and cell survival [34].
Our findings regarding the enhancement of differenti-
ation of WJ-MSCs into IPCs under the effect of exendin-4
are in agreement with previous studies which reported
beneficial effects of exendin-4 for the differentiation of
ESCs and increasing the insulin release by IPCs [22],
MSCs from adipose tissue [35] or BM-MSCs [36].
Interestingly, apart from its beneficial effects on IPC
differentiation, exendin-4 was previously reported to
Fig. 3 Gene expression analyses by qRT-PCR for several β-cell markers. a Pdx-1, b Nkx2.2, c Isl-1 and d MafA in differentiated IPCs derived from
differentiation protocols A and B as compared with their control uninduced WJ-MSCs. Results are presented as mean ± standard error of mean,
obtained from three independent experiments. *Means are significantly different from control uninduced WJ-MSCs at p < 0.05
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increase β-cell mass by stimulating β-cell proliferation and
neogenesis in diabetic rats [26]. However, the exact mech-
anism of action of exendin-4 during the differentiation
process and even its anti-diabetic actions or effects on β
cells in clinical settings (exenatide) are not understood
completely [37]. Among these suggested mechanisms are
the induction of Pdx-1, and acting through several intracel-
lular pathways such as the phosphatidylinositol-3-kinase
(PI3K), the hedgehog or the MAPK/ERK pathway [18].
The suggested mechanism through inducing Pdx-1 was
exhibited in our study by the significantly elevated ex-
pression of Pdx-1 transcript in IPCs generated from
protocol B as compared with its very low expression
levels in those obtained from protocol A.
Although exendin-4 has been implicated extensively
in generation of IPCs from various forms of MSCs in-
cluding BM-MSCs [36], adipose MSCs [38] and even
WJ-MSCs [13], the exact mechanism of exendin-4 on
differentiation of MSCs into IPCs is far from complete
elucidation and studies involved in understanding this
mechanism are scarce. Accordingly, we decided to
study the effect of exendin-4 alone and in combination
with nicotinamide and β-mercaptoethanol in this differ-
entiation process.
Interestingly, our results clearly demonstrated differ-
ent effects of exendin-4 on various β-cell differenti-
ation markers. First, we found that exendin-4 can
alone induce Pdx-1. Moreover, adding nicotinamide
and β-mercaptoethanol caused further induction of
this transcription factor. Several reports have shown
that exendin-4 upregulated Pdx-1 during β-cell regen-
eration and that the effect of exendin-4 on β cells is
mediated by Pdx-1 [39]. Actually, Pdx-1 is important
for early pancreatic development and formation of β
cells, and also acts as an insulin secretion activator
[40]. Moreover, overexpression of Pdx-1 has been im-
plicated in the differentiation of ESCs into IPCs [41].
Our results therefore imply that the improvement of
differentiation outcome induced by exendin-4 might
be mediated by Pdx-1.
In addition to Pdx-1 as an early pancreatic develop-
ment factor, exendin-4 also induced the expression of
Fig. 4 Gene expression analyses by qRT-PCR for cells induced by individual extrinsic factors, namely exendin-4 alone (Ex), exendin-4 plus nicotinamide
(Ex + NA), and exendin-4 plus nicotinamide and β-mercaptoethanol (Ex + NA + BME), in 5 % FBS HG-DMEM. Gene expression analyses were done for
several β-cell-related genes, namely a Pdx-1, b Nkx2.2, c Isl-1 and d MafA presented as relative mRNA expression levels in induced cells relative
to their uninduced control counterparts. Results presented as mean ± standard error of mean for three independent experiments. *Means are
significantly different from control at p < 0.05. #Means are significantly different from exendin-4 alone (Ex) at p < 0.05
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Nkx2.2 transcription factor in WJ-MSCs. Nkx2.2 is im-
plicated in early pancreatic development and, again, its
overexpression induced β-cell differentiation from ESCs
[42, 43]. In contrast to Pdx-1 and Nkx2.2, exendin-4
failed alone to induce Isl-1, another transcription factor
implicated in later endocrine differentiation during pan-
creatic development [44]. However, when exendin-4 was
added with nicotinamide and/or β-mercaptoethanol, all
of them showed some sort of synergism and induced the
expression of Isl-1 significantly as compared with control
noninduced cells and as compared with induction using
exendin-4 alone. Collectively, these results indicate that
exendin-4 can be playing a role in the early development
of IPCs from MSCs through its effect on Pdx-1 and
Nkx2.2, and possibly through Isl-1 in the presence of
nicotinamide and β-mercaptoethanol, but not alone. We
assume this is considered an interesting finding that
confirms not only the need for several factors to achieve
complete differentiation to IPCs, but also reflects the
complicated steps of such a process.
Interestingly, our results demonstrated that MafA
transcript levels could be induced by exendin-4. MafA
controls and activates the expression and secretion of in-
sulin [45]. It is noteworthy here that exendin-4 at the
dose used in our protocols was reported previously to
increase the insulin secretion by β cells differentiated
from ESCs [22]. Moreover, a recent study showed that
proper activation of MafA at a specific stage of β-cell
differentiation is critical for achieving optimum matur-
ation of β cells [46]. Actually, the induced expression of
MafA in the current study was enhanced with the
addition of nicotinamide and β-mercaptoethanol, indi-
cating a synergistic effect of these three factors for better
differentiation of WJ-MSCs into IPCs, with the ultimate
goal of attaining fully differentiated IPCs. This was
clearly reflected in the far better GSIS of the IPCs gener-
ated from protocol B, with exendin-4, than that of
protocol A, as well as the better expression of Pdx-1
protein in IPCs generated from protocol B as compared
with those derived from protocol A. Collectively, these
results clearly demonstrate the importance of exendin-4
in attaining better mature IPCs from WJ-MSCs and,
therefore, improving the differentiation outcome of these
cells.
It is noteworthy here that nicotinamide and β-
mercaptoethanol used together in protocol A could
induce some transcription factors, namely Nkx2.2, Isl-1
and MafA. On the contrary, nicotinamide and β-
mercaptoethanol showed a synergistic effect with
exendin-4 in induction of Pdx-1, Isl-1 and MafA. From
these results one can assume that these extrinsic factors
are acting in a complementary way in the induction of
the complex process of differentiation. Accordingly,
one can recommend, with confidence, using these
extrinsic factors together in order to achieve better
functioning IPCs. Also, we can portray exendin-4 as an
indispensable factor in the differentiation protocols for
WJ-MSCs into IPCs based on the levels of induction of
β-cell markers in protocol B and better functionality
reflected in better GSIS of this protocol.
Collectively, it seems that exendin-4 can induce several
stages in the complex differentiation process, including
the early stages exemplified by Pdx-1 and Nkx2.2, in
addition to late stages of insulin secretion exemplified by
MafA.
This study is one of the few that dissect the role of
exendin-4 on various β-cell markers upon differentiation
of WJ-MSCs. This will be of great help in understanding
the mechanism behind the effect of exendin-4 on the
generation of IPCs from MSCs of different sources.
Interestingly, a recent study by Xin et al. [47] showed
that IPCs differentiated from human BM-MSCs could
ameliorate diabetes in streptozotocin-induced diabetic
nude mice. This implicates that differentiated cells can
find their ways into diabetes regenerative medicine.
However, the existing induction strategies of IPCs from
MSCs need to be modified and improved. Our study is a
step toward better understanding and developing a com-
petent protocol of differentiation that ensures better
functioning IPCs through the utilization of exendin-4
side by side with nicotinamide and β-mercaptoethanol.
In fact, the synergistic effect between exendin-4 with
nicotinamide and β-mercaptoethanol observed in the
induction of expression of several β-cell markers like
Pdx-1, Isl-1 as well as MafA sheds lights on the fact
that the effects of exendin-4 could indeed be affected
greatly by other extrinsic factors. This opens the door
for a wide array of further investigations to study pos-
sible interactions between exendin-4 and other extrin-
sic factors incorporated during the course of various
differentiation protocols in the literature, with the ul-
timate goal of achieving fully mature functional β cells
for cell therapy of diabetes.
Our results demonstrate that exendin-4 greatly en-
hanced the differentiation of WJ-MSCs into IPCs. In
doing so, exendin-4 induced several β-cell markers with
some synergy with nicotinamide and β-mercaptoethanol.
This is considered a step forward toward better under-
standing the differentiation process and achieving better
functioning IPCs from MSCs that can be of value in dia-
betes regenerative medicine.
Conclusions
Our results show that WJ-MSCs represent a readily
available, noninvasive, highly promising source of stem
cells for β-cell replacement therapies. Although the
abundance of literature suggests that generation of IPCs
from stem cells is feasible, many considerations such as
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the cell source, induction protocols and mechanisms of
differentiation should be further explored before the ap-
plication of these cells to clinical settings for treatment
of DM. Most importantly, the principal novel finding of
the current study is the beneficial enhancing effects of
exendin-4 for the differentiation of WJ-MSCs into IPCs.
In addition, this study shows that exendin-4 could in-
duce early and late markers along the differentiation
process. Finally, these findings open the door for further
warranted investigations to gain more in-depth under-
standing of some hidden parts of the story of differenti-
ation of stem cells into IPCs, and the mechanisms of
action of various extrinsic factors. These hidden parts, if
unraveled, will certainly help to resolve the difficulties of
obtaining mature functioning IPCs.
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